SCHEMBL3008166

SCHEMBL3008166

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cc(Cl)ccc3OC)CC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
MAPT P10636 3/20 0.54
TSHR P16473 1/20 0.54
ALDH1A1 P00352 4/20 0.52
RAB9A P51151 2/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
GAA P10253 1/20 0.49
HTT P42858 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALOX12 P18054 1/20 0.45
MEN1 O00255 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011166 0.94 MAPT (0.47) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3002552 0.93 ALDH1A1 (0.50) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3002492 0.93 MAPT (0.45) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3652842 0.92 ALDH1A1 (0.47) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3007189 0.91 ALDH1A1 (0.52) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3017807 0.91 ALDH1A1 (0.61) LMNAMAPTALDH1A1RAB9AKDM4E
SCHEMBL3014333 0.91 ALDH1A1 (0.54) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3019561 0.90 ALDH1A1 (0.51) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL3015128 0.90 GAA (0.51) LMNAMAPTTSHRALDH1A1RAB9A
SCHEMBL2997875 0.90 SMN1; SMN2 (0.45) LMNAMAPTTSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPT 18/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.